Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 2, Pages 1313-1328Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00440
Keywords
-
Categories
Funding
- AbbVie
- Bayer Pharma AG
- Boehringer Ingelheim
- Canada Foundation for Innovation
- Eshelman Institute for Innovation
- Genome Canada
- Genentech
- Innovative Medicines Initiative (EU/EFPIA) [115766]
- Janssen
- Merck KGaA Darmstadt Germany
- MSD
- Novartis Pharma AG
- Ontario Ministry of Economic Development and Innovation
- Pfizer
- Sa~o Paulo Research Foundation-FAPESP
- Takeda
- Wellcome [106169/ZZ14/Z]
- NC Biotechnology Center Institutional Support grant [2018-IDG-1030]
- NIH [1U24DK116204, U54AG065187]
- DoD ALSRP award [AL190107]
- ALS Association grant [wa1127]
Ask authors/readers for more resources
The pyrimidine core has been widely used in constructing kinase inhibitors, and the strategy of utilizing nonexemplified aminopyrimidines with side chains from annotated inhibitors has provided useful inhibitors for understudied kinases. By mixing and matching side chains from parent compounds and modifying the 5-position of the pyrimidine core, improved kinome-wide selectivity was achieved. Important lead compounds for understudied kinases such as DRAK1, BMP2K, and MARK3/4 were also identified through this approach.
The pyrimidine core has been utilized extensively to construct kinase inhibitors, including eight FDA-approved drugs. Because the pyrimidine hinge-binding motif is accommodated by many human kinases, kinome-wide selectivity of resultant molecules can be poor. This liability was seen as an advantage since it is well tolerated by many understudied kinases. We hypothesized that nonexemplified aminopyrimidines bearing side chains from well-annotated pyrimidine-based inhibitors with off-target activity on understudied kinases would provide us with useful inhibitors of these lesser studied kinases. Our strategy paired mixing and matching the side chains from the 2- and 4-positions of the parent compounds with modifications at the 5-position of the pyrimidine core, which is situated near the gatekeeper residue of the binding pocket. Utilizing this approach, we imparted improved kinome-wide selectivity to most members of the resultant library. Importantly, we also identified potent biochemical and cell-active lead compounds for understudied kinases like DRAK1, BMP2K, and MARK3/4.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available